Sociedad Americana de Hirudoterapia

Cutaneous Pseudolymphoma Due to Hirudotherapy

Research article published in Turkiye parazitolojii dergisi (2019)

Última actualización: March 18, 2026Revisado por: ASH Editorial Board
Research article — evidence reviewArticle reference
Ensayos clínicosTemiz S et al. · Turkiye parazitolojii dergisi, 2019

Abstract

Pseudolymphoma, also known as Jessner’s lymphocytic infiltration, is a benign but usually chronic, T-cell infiltrating disease with erythematous papules and plaques usually seen on the skin of the face, neck, and back. The use of leech therapy also known as hirudotherapy has increased in recent years. Here, we report a 52-year-old male patient who had undergone hirudotherapy in his neck and developed infiltrating plaques after four months. A skin biopsy confirmed the diagnosis of Jessner’s lymphocytic infiltration. In parallel with the increasing use of hirudotherapy in recent years, the side-effect reports will likely to increase. Indications and contraindications of hirudotherapy, which is being used officially in hospitals, should be taken into consideration.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeCase ReportsJournal Article
Indexed MeSH termsDiagnosis, DifferentialHumansLeechingMaleMiddle AgedNeckPseudolymphomaSkin Diseases

Resumen

Pseudolymphoma, also known as Jessner’s lymphocytic infiltration, is a benign but usually chronic, T-cell infiltrating disease with erythematous papules and plaques usually seen on the skin of the face, neck, and back.

Por qué esto importa para la hirudoterapia

Contributes clinical evidence for the therapeutic application of leech therapy.

Citación

Cutaneous Pseudolymphoma Due to Hirudotherapy.

Temiz S et al. · Turkiye parazitolojii dergisi, 2019

Contexto clínico relacionado

Añadido a la biblioteca ASH: March 18, 2026 · Última actualización del sitio: March 18, 2026

Este sitio web proporciona información educativa y no constituye consejo médico, diagnóstico ni recomendaciones de tratamiento. La terapia con sanguijuelas medicinales conlleva riesgos clínicamente significativos y debe ser realizada únicamente por profesionales calificados bajo protocolos aprobados institucionalmente. La autorización 510(k) de la FDA para sanguijuelas medicinales se limita a indicaciones específicas; las discusiones sobre uso investigativo y fuera de indicación se señalan correspondientemente. Para orientación médica específica, consulte a un profesional de salud calificado.

Cutaneous Pseudolymphoma Due to Hirudotherapy | ASH